Literature DB >> 2556712

Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes.

T D Chung1, F H Drake, K B Tan, S R Per, S T Crooke, C K Mirabelli.   

Abstract

Several DNA topoisomerase II (Topo II; EC 5.99.1.3) partial cDNA clones obtained from a human Raji-HN2 cDNA library were sequenced and two classes of nucleotide sequences were found. One member of the first class, SP1, was identical to an internal fragment of human HeLa cell Topo II cDNA described earlier. A member of the second class, SP11, shared extensive nucleotide (75%) and predicted peptide (92%) sequence similarities with the first two-thirds of HeLa Topo II. Each class of cDNAs hybridized to unique, nonoverlapping restriction enzyme fragments of genomic DNA from several human cell lines. Synthetic 24-mer oligonucleotide probes specific for each cDNA class hybridized to 6.5-kilobase mRNAs; furthermore, hybridization of probe specific for one class was not blocked by probe specific for the other. Antibodies raised against a synthetic SP1-encoded dodecapeptide specifically recognized the 170-kDa form of Topo II, while antibodies raised against the corresponding SP11-encoded dodecapeptide, or a second unique SP11-encoded tridecapeptide, selectively recognized the 180-kDa form of Topo II. These data provide genetic and immunochemical evidence for two Topo II isozymes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2556712      PMCID: PMC298510          DOI: 10.1073/pnas.86.23.9431

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Authors:  F H Drake; G A Hofmann; H F Bartus; M R Mattern; S T Crooke; C K Mirabelli
Journal:  Biochemistry       Date:  1989-10-03       Impact factor: 3.162

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Identification of the breakage-reunion subunit of T4 DNA topoisomerase.

Authors:  T C Rowe; K M Tewey; L F Liu
Journal:  J Biol Chem       Date:  1984-07-25       Impact factor: 5.157

4.  Novel topologically knotted DNA from bacteriophage P4 capsids: studies with DNA topoisomerases.

Authors:  L F Liu; J L Davis; R Calendar
Journal:  Nucleic Acids Res       Date:  1981-08-25       Impact factor: 16.971

Review 5.  DNA topoisomerases.

Authors:  M Gellert
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

6.  A comprehensive set of sequence analysis programs for the VAX.

Authors:  J Devereux; P Haeberli; O Smithies
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

7.  A new computer method for the storage and manipulation of DNA gel reading data.

Authors:  R Staden
Journal:  Nucleic Acids Res       Date:  1980-08-25       Impact factor: 16.971

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  DNA topoisomerase II from Drosophila melanogaster. Purification and physical characterization.

Authors:  E R Shelton; N Osheroff; D L Brutlag
Journal:  J Biol Chem       Date:  1983-08-10       Impact factor: 5.157

10.  Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster.

Authors:  M Sander; T Hsieh
Journal:  J Biol Chem       Date:  1983-07-10       Impact factor: 5.157

View more
  58 in total

1.  Sp1 mediates cell proliferation-dependent regulation of rat DNA topoisomerase IIalpha gene promoter.

Authors:  J H Yoon; J K Kim; G B Rha; M Oh; S H Park; R H Seong; S H Hong; S D Park
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Cellular distribution of mammalian DNA topoisomerase II is determined by its catalytically dispensable C-terminal domain.

Authors:  N Adachi; M Miyaike; S Kato; R Kanamaru; H Koyama; A Kikuchi
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.

Authors:  D W Stacey; M Hitomi; G Chen
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Regulation of DNA Topoisomerase IIbeta through RNA-dependent association with heterogeneous nuclear ribonucleoprotein U (hnRNP U).

Authors:  Shinji Kawano; Mary Miyaji; Shoko Ichiyasu; Kimiko M Tsutsui; Ken Tsutsui
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

5.  The cell cycle-coupled expression of topoisomerase IIalpha during S phase is regulated by mRNA stability and is disrupted by heat shock or ionizing radiation.

Authors:  P C Goswami; J L Roti Roti; C R Hunt
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 6.  SUMO modification of DNA topoisomerase II: trying to get a CENse of it all.

Authors:  Ming-Ta Lee; Jeff Bachant
Journal:  DNA Repair (Amst)       Date:  2009-02-20

7.  cin-4, a gene with homology to topoisomerase II, is required for centromere resolution by cohesin removal from sister kinetochores during mitosis.

Authors:  Gerald Stanvitch; Landon L Moore
Journal:  Genetics       Date:  2008-01       Impact factor: 4.562

8.  The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage.

Authors:  Timothy J Wendorff; Bryan H Schmidt; Pauline Heslop; Caroline A Austin; James M Berger
Journal:  J Mol Biol       Date:  2012-07-25       Impact factor: 5.469

9.  Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.

Authors:  G J Finlay; K M Holdaway; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cells.

Authors:  Gaetano Marverti; Alessio Ligabue; Monica Montanari; Davide Guerrieri; Matteo Cusumano; Maria Letizia Di Pietro; Leonarda Troiano; Elena Di Vono; Stefano Iotti; Giovanna Farruggia; Federica Wolf; Maria Giuseppina Monti; Chiara Frassineti
Journal:  Invest New Drugs       Date:  2009-10-16       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.